According to Philips’ latest annual global survey on ‘Better Sleep, Better Health’, more than 100 million people suffer from sleep apnea globally. Above 80 percent of these people remain undiagnosed and 30 percent find it difficult to initiate and maintain sleep. Studies have established that about 7-9% Indian adult population suffer from Sleep Apnea.2
In line with its commitment to create awareness about sleep disorders in India, Philips continue to educate people about extreme symptoms such as loud snoring, unwarranted daytime sleepiness, poor concentration and its impact on health as well as overall quality of life.3 Studies have shown the relationship between sleep apnea and cardiovascular diseases, with people having severe sleep apnea being more likely to develop congestive heart failure.4
As one of the leading causes of death worldwide, chronic obstructive pulmonary disease (COPD) affects more than 251 million people. While millions of people across the globe have been diagnosed with COPD, there are millions of others who remain undiagnosed, or have been labeled incorrectly with a different lung condition.5 Philips Respironics is committed to providing one unified approach to COPD care – coordinated, consistent, uninterrupted and centered around the patient. Our goal is to help reduce hospitalizations, improve patient care, maximize clinician resources and support patients in living more-active, fulfilling lives.6
Philips’ sleep and respiratory solutions enable patients to rediscover their confidence and freedom to live a fulfilling life by restoring their ability to sleep and breathe better while simultaneously enabling more efficient care. The 'No-cost EMI' scheme on Sleep & Respiratory care products further demonstrates Philips’ efforts to ensure affordable and accessible care to patients in India.
Reiterating its commitment to ‘Sleep Health’, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced a 'No-cost EMI' offer on its products under the Respironics range of sleep and respiratory solutions. These solutions will assist patients suffering from Chronic Obstructive Pulmonary Disease (COPD), a lung disease with long-term breathing problems and Obstructive Sleep Apnea (OSA), a chronic condition where the patient experiences interrupted breathing during sleep.